tetano
Editor, Senior Moderator
JACC Heart Fail. 2017 Jan 28. pii: S2213-1779(17)30044-6. doi: 10.1016/j.jchf.2016.12.007. [Epub ahead of print]
[h=1]Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.[/h] Bhatt AS[SUP]1[/SUP], DeVore AD[SUP]2[/SUP], Hernandez AF[SUP]2[/SUP], Mentz RJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Heart failure (HF) is a chronic syndrome characterized by acute exacerbations. There is significant overlap between respiratory infections and exacerbation of underlying HF. Vaccination against respiratory infections in patients with HF could serve as a potential cost-effective intervention to improve patients' quality of life and clinical outcomes. The benefits of influenza vaccination in secondary prevention of ischemic heart disease have been previously studied. However, the evidence for influenza and pneumococcal vaccination specifically in the HF population is less well established. Furthermore, questions around the optimal timing, dose, frequency, and implementation strategies are largely unanswered. This review highlights the current evidence for vaccination against influenza and pneumococcal pneumonia in HF and cardiovascular disease. It summarizes current understanding of the pathophysiologic mechanisms in which vaccination may provide cardioprotection. Finally, it offers opportunities for further investigation of the effects of vaccination in the HF population, spanning basic science, translational research, and large clinical trials.
Copyright ? 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] heart failure; influenza; pneumococcal; vaccination
PMID: 28161238 DOI: 10.1016/j.jchf.2016.12.007
[PubMed - as supplied by publisher]
[h=1]Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.[/h] Bhatt AS[SUP]1[/SUP], DeVore AD[SUP]2[/SUP], Hernandez AF[SUP]2[/SUP], Mentz RJ[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Heart failure (HF) is a chronic syndrome characterized by acute exacerbations. There is significant overlap between respiratory infections and exacerbation of underlying HF. Vaccination against respiratory infections in patients with HF could serve as a potential cost-effective intervention to improve patients' quality of life and clinical outcomes. The benefits of influenza vaccination in secondary prevention of ischemic heart disease have been previously studied. However, the evidence for influenza and pneumococcal vaccination specifically in the HF population is less well established. Furthermore, questions around the optimal timing, dose, frequency, and implementation strategies are largely unanswered. This review highlights the current evidence for vaccination against influenza and pneumococcal pneumonia in HF and cardiovascular disease. It summarizes current understanding of the pathophysiologic mechanisms in which vaccination may provide cardioprotection. Finally, it offers opportunities for further investigation of the effects of vaccination in the HF population, spanning basic science, translational research, and large clinical trials.
Copyright ? 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
[h=4]KEYWORDS:[/h] heart failure; influenza; pneumococcal; vaccination
PMID: 28161238 DOI: 10.1016/j.jchf.2016.12.007
[PubMed - as supplied by publisher]